India's Biocon Biologics in funding talks with Baring PE Asia

NEW DELHI -- Biocon Biologics, a unit of India's largest biopharmaceutical company Biocon, is in talks with Asia-focused Baring Private Equity Asia to raise funding in lieu of a minority stake, sources familiar with the matter told DealStreetAsia.

While the exact size of the deal is unknown, it could be worth around $100 million or more, the sources said.